Pneumococcal vaccine polyvalent

(Pneumovax 23®)

Pneumococcal vaccine polyvalent

Drug updated on 4/17/2024

Dosage FormInjection (intramuscular/subcutaneous; 0.5 mL)
Drug ClassVaccines
Ongoing and
Completed Studies


  • Indicated for the active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Latest News

loading GIF

This AI-generated content is provided without warranty and may be inaccurate or outdated, with no liability accepted for reliance on it. Learn more.

  • Pneumovax 23 (pneumococcal vaccine polyvalent) is indicated for the active immunization for the prevention of pneumococcal disease caused by specific serotypes contained in the vaccine.
  • Six studies were reviewed, providing insights into Pneumovax 23's use across different populations and its comparison to newer pneumococcal conjugate vaccines (PCVs).
  • Compared to PCV13, PCV15, and PCV20, Pneumovax 23 shows lower effectiveness against pneumococcus pneumonia but similar utility in preventing invasive pneumococcal diseases.
  • For workers exposed to welding fumes who are at increased risk of IPD, a dose of PPSV23 is recommended, with consideration towards using newer recombinant formulas for broader protection.
  • In adults living with HIV or undergoing dialysis treatment, combining vaccinations such as influenza vaccination along with timing strategies can improve outcomes, including reduced all-cause mortality and cardiovascular events.
  • Elderly individuals over age 65 may experience additional benefits from receiving this vaccination beyond direct infection prevention due to decreased risk for some cardiovascular events.

Product Monograph / Prescribing Information

Document TitleYearSource
Pneumovax (pneumococcal vaccine polyvalent) Prescribing Information.2023Merck Sharp & Dohme LLC, Rahway, NJ

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines